usp專利下載

1、USP是什麼意思？？

usp策略——羅瑟·瑞夫斯《實效廣告》
即「獨特的銷售主張（unique sales proposition）」
1.每一則廣告必須向消費者「說一個主張，必須讓消費者明白購買廣告中的產品可以獲得什麼具體利益」；
2.所強調的主張必須是競爭對手做不到的或者無法提供的，必須說出其獨特之處，在品牌和訴求方面是獨一無二的；
3.所強調的主張必須是強而有力的，必須聚集在一個點上，集中打動，感動和引導消費者來買相應的產品。

2、USP是什麼意思?

usp美國葯典，目前有兩種定義。

一種是美聯邦對葯品質量標准和檢定方法作出的技術規定的作為一個獨立的、非盈利性的非政府組織。USP發布的標准已被全球130多個國家(地區)所認同。

第二種是上面介紹定義的機構出版物usp美國葯典。

usp美國葯典是美聯邦對葯品質量標准和檢定方法作出的技術規定，是企業、單位、機構等生產、使用、管理、檢驗葯品、化學品、化工品的法律依據。

(2)usp專利下載擴展資料

usp在中國

由於中國醫葯企業的迅猛發展，usp美國葯典也於2007年在中國設立總部，正式征戰大中華地區的認證業務。

3、電腦主機上的USP是什麼???

USP：United States Patent 美國專利
USP：United States Pharmacopoeia 美國葯典
USP：User Stack Pointer 用戶堆棧指針
USP：Universal Selbstlade Pistol 通用自動裝填手槍
USP：Unique Selling Proposition 獨特銷售主張
USP：University of the South Pacific 南太平洋大學
USP：University of São Paulo 聖保羅大學
USP：University of the Sciences in Philadelphia 費城理科大學

不知道你的電腦主機上的USP代表的是何種意思。

4、求高手查一下這個專利，公開號：us2145952A。最好有文檔

Bibliographic data: US2145952 (A) ― 1939-02-07

這個老美的專利時間可有點久哦，看看是不是這個？

優先權日期都是1937年了。。。

名稱是 Vehicle bumper。

下載地址：

http://www4.drugfuture.com/uspat/download/US2145952.pdf

不用謝我，請叫我雷鋒~

5、USP的英文全稱

USP即「獨特的銷售主張」(Unique Selling Proposition)表示
獨特的銷售主張或「獨特的賣點」，「USP」是羅瑟·瑞夫斯（Rosser Reeves）在20世紀50年代首創的，他當時是美國Ted Bates廣告公司董事長。里夫斯比較早地意識到廣告必須引發消費者的認同。他認為，USP是消費者從廣告中得到的東西，而不是廣告人員硬性賦予廣告的東西

6、usp是什麼意思？

1、USP

英文縮寫：USP

英文全稱：US Patent

中文解釋：美國專利

縮寫分類：自科總論、常用詞彙

縮寫簡介：The United States Patent美國專利

2、USP

英文縮寫：USP

英文全稱：The united states pharmacopoeia

中文解釋：《美國葯典》

縮寫分類：醫葯衛生

3、USP

英文縮寫：USP

英文全稱：unique selling proposition

中文解釋：獨特銷售理論

縮寫分類：經濟管理

4、usp

英文縮寫：usp

英文全稱：Universal Selbstlade Pistole

中文解釋：通用自動裝填手槍

縮寫分類：軍事政治

(6)usp專利下載擴展資料：

重點詞彙：united

英［ju＇naɪtɪd］

釋義：

adj.一致的，統一的；團結的，和睦的

短語：

United Kingdom英國；聯合王國；最尊崇天才的英國；國家

7、usp對照品說明書如何下載

USP對照品說明書可以自助查詢，

首先進入USP網站，然後在搜索框內輸入您需要查詢產品的編號，比如1000829

然後點擊搜索就會得到相應的產品信息，說明書也包含在內

8、美國葯典中文版下載

5月16日 15:46 現行為USP 29-NF 24

USP 29-NF 24 的正式有效日期是 2006 年 1 月 1 日至 2006 年 12 月 31 日。

具體可參考美國葯典網站，現已有中文網頁：http://www.usp.org/USPNF/

9、急求:所謂的美國專利USP4493902的具體內容是什麼??

United States Patent 4,493,902
Brown , et al. January 15, 1985

--------------------------------------------------------------------
Fluid catalytic cracking catalyst comprising microspheres containing more than about 40 percent by weight Y-faujasite and methods for making

Abstract
This application discloses novel fluid catalytic cracking catalysts comprising microspheres containing more than about 40%, preferably 50-70%, by weight Y-faujasite zeolite, methods for making such catalysts, and the use of such catalysts to crack petroleum feedstocks, particularly those containing large amounts of contaminant metals. The microspheres of the catalyst of the invention are characterized by a combination of desirable catalytic and physical characteristics, including exceptionally high activity, excellent hydrothermal stability, good to excellent attrition resistance, and desirable selectivity characteristics.

--------------------------------------------------------------------------------
Inventors: Brown; Stanley M. (Scotch Plains, NJ), Durante; Vincent A. (East Brunswick, NJ), Reagan; William J. (Englishtown, NJ), Speronello; Barry K. (River Edge, NJ)
Assignee: Engelhard Corporation (Iselin, NJ)

Appl. No.: 06/469,765
Filed: February 25, 1983

--------------------------------------------------------------------------------

詳細內容不介紹了，美國國家專利局網站就免費提供全文（full text），含圖的，自己下載看看：
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4493902.PN.&OS=PN/4493902&RS=PN/4493902

10、請問，誰能下載到USP35 1225 VERIFICATION OF COMPENDIAL PROCEDURES的內容？

1226 VERIFICATION OF COMPENDIAL PROCEDURES
The intent of this general information chapter is to provide general information on the verification of compendial proceres that are being performed for the first time to yield acceptable results utilizing the personnel, equipment, and reagents available. This chapter is not intended for retroactive application to already successfully established laboratory proceres. The chapter Validation of Compendial Proceres 1225 provides general information on characteristics that should be considered for various test categories and on the documentation that should accompany analytical proceres submitted for inclusion in USP–NF. Verification consists of assessing selected analytical performance characteristics, such as those that are described in chapter 1225, to generate appropriate, relevant data rather than repeating the validation process.
Users of compendial analytical proceres are not required to validate these proceres when first used in their laboratories, but documented evidence of suitability should be established under actual conditions of use. In the United States, this requirement is established in 21 CFR 211.194(a)(2) of the current Good Manufacturing Practice regulations, which states that the 「suitability of all testing methods used shall be verified under actual conditions of use.」
Verification of microbiological proceres is not covered in this chapter because it is covered in USP general test chapters Antimicrobial Effectiveness Testing 51, Microbiological Examination of Nonsterile Procts: Microbial Enumeration Tests 61, Microbiological Examination of Nonsterile Procts: Tests for Specified Microorganisms 62, Sterility Tests 71, and in general information chapter Validation of Microbial Recovery from Pharmacopeial Articles 1227.
Change to read:

VERIFICATION PROCESS
The verification process for compendial test proceres is the assessment of whether the procere can be used for its intended purpose, under the actual conditions of use for a specified drug substance and/or drug proct matrix.USP35
Users should have the appropriate experience, knowledge, and training to understand and be able to perform the compendial proceres as written. Verification should be concted by the user such that the results will provide confidence that the compendial procere will perform suitably as intended.
If the verification of the compendial procere is not successful, and assistance from USP staff has not resolved the problem, it may be concluded that the procere may not be suitable for use with the article being tested in that laboratory. It may then be necessary to develop and validate an alternate procere as allowed in the General Notices. The alternate procere may be submitted to USP, along with the appropriate data, to support a proposal for inclusion or replacement of the current compendial procere.
Change to read:

VERIFICATION REQUIREMENTS
Verification requirements should be based on an assessment of the complexity of both the procere and the material to which the procere is applied. Although complete revalidation of a compendial method is not required to verify the suitability of a procereUSP35 under actual conditions of use, some of the analytical performance characteristics listed in chapter 1225, Table 2, may be used for the verification process. Only those characteristics that are considered to be appropriate for the verification of the particular procereUSP35 need to be evaluated. The process of assessing the suitability of a compendial analytical test procere under the conditions of actual use may or may not require actual laboratory performance of each analytical performance characteristic.USP35 The degree and extent of the verification process may depend on the level of training and experience of the user, on the type of procere and its associated equipment or instrumentation, on the specific proceral steps, and on which article(s) are being tested.
Verification should assess whether the compendial procere is suitable for the drug substance and/or the drug proct matrix, taking into account the drug substance's synthetic route, the method of manufacture for the drug proct, or both, if applicable. Verification should include an assessment of elements such as the effect of the matrix on the recovery of impurities and drug substances from the drug proct matrix, as well as the suitability of chromatographic conditions and column, the appropriateness of detector signal response, etc.USP35
As an example, an assessment of specificity is a key parameter in verifying that a compendial procere is suitable for use in assaying drug substances and drug procts. For instance, acceptable specificity for a chromatographic method may be verified by conformance with system suitability resolution requirements (if specified in the procere).USP35 However, drug substances from different suppliers may have different impurity profiles that are not addressed by the compendial test procere. Similarly, the excipients in a drug proct can vary widely among manufacturers and may have the potential to directly interfere with the procere or cause the formation of impurities that are not addressed by the compendial procere. In addition, drug procts containing different excipients, antioxidants, buffers, or container extractives may affect the recovery of the drug substance from the matrix.USP35 In these cases, a more thorough assessment of the matrix effectsUSP35 may be required to demonstrate suitability of the procereUSP35 for the particular drug substance or proct. Other analytical performance characteristics such as an assessment of the limit of detection or quantitation and precision for impurities proceres may be useful to demonstrate the suitability of the compendial procereUSP35 under actual conditions of use.
Verification is not required for basic compendial test proceres that are routinely performed unless there is an indication that the compendial procere is not appropriate for the article under test. Examples of basic compendial proceres include, but are not limited to, loss on drying, resie on ignition, various wet chemical proceres such as acid value, and simple instrumental determinationsUSP35 such as pH measurements. However, for the application of already established routine proceres to compendial articles tested for the first time, it is recommended that consideration be given to any new or different sample handling or solution preparation requirements.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
General Chapter Horacio N. Pappa, Ph.D.
Principal Scientific Liaison
1-301-816-8319 (GCPA2010) General Chapters - Physical Analysis

USP35–NF30 Page 882
Pharmacopeial Forum: Volume No. 36(6) Page 1775

1226是VERIFICATION &1225是VALIDATION ，跟您的提問有點出入，本想兩個都貼上來，可是奈何篇幅太長，知道發不出。
1226&1225具體內容已發送至郵箱，請查收！